Companies › Compass Therapeutics
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CTX-009 Bispecific antibody | – | Phase 2 | Biliary Tract Cancer; Glioblastoma | Aug 2027 |
| CTX-8371 Unclear - mechanism not stated in registry | – | Phase 1 | Non Small Cell Lung Cancer | Dec 2026 |
| CTX-10726 | – | Phase 1 | Gastroesophageal Cancer (GC) | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06150664 | CTX-8371 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05506943 | CTX-009 | Phase 2 | Biliary Tract Cancer | Oncology | Aug 2027 |
| NCT07419841 | CTX-10726 | Phase 1 | Gastroesophageal Cancer (GC) | Oncology | Apr 2028 |
| NCT07392957 | CTX-009 | Phase 1 | Glioblastoma | Oncology | Jun 2029 |
Cash and short-term investments of $163m on 2026-09-30; operating cash outflow about $65m a year; runway about 30 months at that burn, to Apr 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Nurix Therapeutics Puma Biotechnology Tianjin ConjuStar Biologics Avistone Biotechnology Day One Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.